Are patients with stage III non-small cell lung cancer treated with chemoradiotherapy at risk for cardiac events? Results from a retrospective cohort study.
Juliette H R J DegensD De RuysscherRuud HoubenBastiaan KietselaerGerben BootsmaLizza HendriksEllen HuijbersAnnemie ScholsAnne-Marie C DingemansPublished in: BMJ open (2020)
One-third of patients with stage III NSCLC treated in daily clinical practice develop a new cardiac event within 5 years after CRT. All physicians confronted with patients with NSCLC should take cardiac comorbidity as a serious possible explanation for dyspnoea after treatment with CRT.